Based on recent review of studies showing that the diabetes drug canagliflozin (Invokana) has many benefits for heart and kidney disease, and that the risk of amputation, while still increased with canagliflozin, is lower than previously described, the FDA has concluded that the boxed warning for increased amputation risk should be removed.  It is still important that patients who are taking Invokana are carefully monitored for any signs of increased amputation risk. Read more